Cutler Group LP Reata Pharmaceuticals Inc Call Options Transaction History

Cutler Group LP

$307 Million
Q1 2024

Call Options

17 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Jul 18, 2023	SELL	$79.22 - $105.37 $1.12 Million - $1.49 Million	-14,100 Reduced 47.16%	15,800 $287,000
Q1 2023 May 01, 2023	BUY	$30.85 - $93.17 $891,565 - $2.69 Million	28,900 Added 2890.0%	29,900 $349,000
Q4 2022 Feb 07, 2023	SELL	$22.15 - $42.11 $8,860 - $16,844	-400 Reduced 28.57%	1,000 $3,000
Q3 2022 Oct 25, 2022	BUY	$19.41 - $36.49 $11,646 - $21,894	600 Added 75.0%	1,400 $5,000
Q2 2022 Aug 04, 2022	SELL	$20.71 - $36.5 $333,431 - $587,650	-16,100 Reduced 95.27%	800 $3,000
Q1 2022 Apr 14, 2022	SELL	$24.12 - $39.6 $84,420 - $138,600	-3,500 Reduced 17.16%	16,900 $42,000
Q4 2021 Jan 18, 2022	BUY	$25.61 - $110.96 $519,883 - $2.25 Million	20,300 Added 20300.0%	20,400 $10,000
Q2 2021 Jul 19, 2021	SELL	$78.27 - $151.29 $15,654 - $30,258	-200 Reduced 66.67%	100 $1,000
Q1 2021 Apr 26, 2021	BUY	$94.25 - $132.81 $9,425 - $13,281	100 Added 50.0%	300 $0
Q4 2020 Jan 21, 2021	SELL	$102.03 - $184.62 $1.1 Million - $1.99 Million	-10,800 Reduced 98.18%	200 $6,000
Q1 2020 May 07, 2020	SELL	$124.16 - $247.74 $248,320 - $495,480	-2,000 Reduced 15.38%	11,000 $208,000
Q4 2019 Feb 06, 2020	BUY	$74.57 - $217.92 $298,280 - $871,680	4,000 Added 44.44%	13,000 $771,000
Q3 2019 Oct 28, 2019	BUY	$71.26 - $95.75 $591,458 - $794,725	8,300 Added 1185.71%	9,000 $87,000
Q2 2019 Aug 09, 2019	SELL	$77.72 - $94.35 $178,756 - $217,005	-2,300 Reduced 76.67%	700 $9,000
Q1 2019 May 10, 2019	SELL	$51.9 - $101.79 $301,020 - $590,382	-5,800 Reduced 65.91%	3,000 $4,000
Q3 2018 Nov 07, 2018	BUY	$35.64 - $92.06 $299,376 - $773,304	8,400 Added 2100.0%	8,800 $78,000
Q2 2018 Aug 10, 2018	BUY	$19.94 - $40.96 $7,976 - $16,384	400 New	400 $0

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account